-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Venous (Vein) Thrombosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abelacimab in Venous (Vein) Thrombosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Venous (Vein) Thrombosis Drug Details: Abelacimab is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma Drug Details: Motixafortide is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Atrial Fibrillation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Atrial Fibrillation Drug Details: Abelacimab is under development for the prevention of venous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Deep Vein Thrombosis (DVT)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Deep Vein Thrombosis (DVT) Drug Details: Abelacimab is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Ischemic Stroke
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Ischemic Stroke Drug Details: Abelacimab is under development for the prevention of venous...
-
Product Insights
NewPulmonary Embolism – Drugs In Development, 2024
Empower your strategies with our Pulmonary Embolism – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat, and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics. The Pulmonary Embolism drugs in development market research...
-
Product Insights
NewVenous (Vein) Thrombosis – Drugs In Development, 2024
Empower your strategies with our Venous (Vein) Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition characterized by the formation of blood clots in veins, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically manifests in deep veins, commonly in the lower leg, thigh, or pelvis, and can extend to the arms, particularly with intravenous central lines. Pulmonary embolism occurs when a detached clot travels to the lungs. With...
-
Product Insights
NewAtrial Fibrillation – Drugs In Development, 2024
Empower your strategies with our Atrial Fibrillation – Drugs In Development, 2024 report and make more profitable business decisions. Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery. The Atrial Fibrillation drugs in development market research...
-
Product Insights
NewDeep Vein Thrombosis (DVT) – Drugs In Development, 2024
Empower your strategies with our Deep Vein Thrombosis (DVT) – Drugs In Development, 2024 report and make more profitable business decisions. Deep vein thrombosis (DVT) is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema), and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a...
-
Product Insights
NewVenous Thromboembolism – Drugs In Development, 2024
Empower your strategies with our Venous Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein and blocks the blood flow. VTE can affect the deep veins of the legs or arms (deep vein thrombosis, or DVT) or the lungs (pulmonary embolism, or PE). VTE can cause serious complications such as tissue damage, organ failure, or death. VTE can be provoked by...